Resilience and Transformation: Pharmaceutical Stock Performance in 2023

As the dust settled from the COVID-19 pandemic, the year 2023 marked a turning point for the pharmaceutical industry. With the economy gradually recovering, experts predicted a rebound in the pharmaceutical securities market. This article explores the key trends and performance of pharmaceutical stocks during this pivotal year.

1. Increased Number of Listed Companies:

According to analysis by Donghai Securities, the total number of A-share pharmaceutical and biotech companies increased from 229 in 2015 to 491 by November 30, 2023, nearly doubling in just eight years. The market value distribution of these companies revealed that 38% had a market capitalization of less than 5 billion yuan, 26% fell between 5 to 10 billion yuan, and 31% ranged from 10 to 50 billion yuan. The total market capitalization of A-share pharmaceutical and biotech companies reached a staggering 7.3 trillion yuan.

2. Performance of A-share Stocks:

In 2023, the pharmaceutical and biotech sector experienced an overall decline of 7.05% in A-share stocks, ranking 16th out of the 31 industries tracked by Donghai Securities. Among the sub-sectors, only the chemical pharmaceutical industry saw a modest increase of 1.29%, while the rest recorded declines. The healthcare services sector suffered the largest decline at 24.46%, followed by pharmaceutical retail (-8.81%) and medical devices (-7.61%). Biologics and traditional Chinese medicine (TCM) II declined by 6.46% and 1.32%, respectively. The price-to-earnings (PE) ratio for the pharmaceutical and biotech sector stood at 27.8, reaching a historic low. Within the sub-sectors, medical devices had the highest PE ratio (32.3), while pharmaceutical retail had the lowest (16.6). Chemical pharmaceuticals, healthcare services, biologics, and TCM followed in descending order.

3. Top 10 Performers:

Among the A-share pharmaceutical companies, eight had a total market capitalization exceeding 100 billion yuan, three exceeded 200 billion yuan, and only one surpassed 300 billion yuan. The highest market value was achieved by Medtronic (352.3 billion yuan), the only company to exceed 300 billion yuan. Hengrui Medicine (288.5 billion yuan) and WuXi AppTec (215.7 billion yuan) ranked second and third, respectively. Hengrui Medicine was the only company that experienced a 17% increase, while Medtronic (-8%) and WuXi AppTec (-9%) faced declines. Among the top 20 companies, three were TCM enterprises: Pien Tze Huang (146 billion yuan), Yunnan Baiyao (88.3 billion yuan), and Tong Ren Tang (73.6 billion yuan). Except for Tong Ren Tang, which grew by 20%, Pien Tze Huang (-16%) and Yunnan Baiyao (-10%) experienced declines. Pien Tze Huang was the only TCM company with a market capitalization exceeding 100 billion yuan. Two medical device companies, Medtronic and Lianluo Smart, and two vaccine companies, CanSino Biologics and Wanhua Bio, were also included in the top 20 performers.

4. Performance of H-share Stocks:

In the Hong Kong stock market, traditional pharmaceutical companies excluding healthcare equipment, medical and beauty services, drug distribution, and biotechnology experienced notable market value growth in 2023. Jilin Changlong Pharmaceutical saw the highest increase, growing by 4.17 times, driven by both special dividends and strong performance. Jintongzi's market value also doubled, surging by 116%. China National Medicines Corporation and White Flower Oil turned losses into profits, with growth rates of 95% and 63% respectively, ranking third and fifth in terms of growth. Saisun Pharmaceutical experienced a 76% increase, while Dongyang Sunshine Jiangsu Pharmaceutical's market value surged by 46% due to the resurgence of its anti-influenza drug, "Oseltamivir." Among the top 10 performers, four were TCM companies: Jintongzi (+116%, 2.5 billion yuan), White Flower Oil (+6%, 600 million yuan), Zhongzhi Pharmaceutical (+51%, 1.2 billion yuan), and Kangchen Pharmaceutical (+33%, 3.9 billion yuan). Kangchen Pharmaceutical has emerged as a rising star in the TCM industry in recent years.

The pharmaceutical stock market in 2023 showcased a mixed performance. While the overall A-share market experienced a decline, the number of listed pharmaceutical companies increased significantly. The top performers demonstrated resilience and adaptability, with TCM companies making their mark alongside medical device and vaccine enterprises. The market's low PE ratio suggested potential opportunities for investors. As thepharmaceutical industry continues to evolve and respond to global health challenges, investors should closely monitor the market dynamics and individual company performance to make informed investment decisions in the coming years.